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Reactive oxygen species formation and release of pro-
inflammatory/pro-atherogenic cytokines, that is, interleukin
1-b and tumor necrosis factor-a, need the activation of the
arachidonic acid cascade via the enzyme 5-lipoxygenase
(5-Lox). 5-Lox activity and expression are significantly
increased in peripheral blood mononuclear cells (PBMCs)
of end-stage renal disease (ESRD) patients on maintenance
hemodialysis (HD). Diets enriched with n-3 polyunsaturated
fatty acids (PUFAs) (x-3) have been associated to a lower
incidence of coronary heart disease (CHD) and a reduction
in atherosclerotic lesions. X-3 may interfere with the
arachidonic acid cascade by inhibiting 5-Lox. Lipid
peroxidation, leukotriene B4 (LTB4) production, 5-Lox activity
and expression were investigated in PBMC isolated from
ESRD patients under maintenance HD before and after a
3-month oral supplementation with x-3 at a daily dose of
2700 mg of n-3 PUFAs at the average eicosapentaenoic
acid/docosaesaenoic acid ratio of 1.2 and finally after a
further 3-month washout with no x-3 supplementation.
PBMCs from non-uremic volunteers were also investigated
for comparison to normal parameters. Administration of
x-3 reduced significantly lipid peroxidation (Po0.0001),
LTB4 synthesis (Po0.0001) and 5-Lox activity (Po0.0001),
with no effect on 5-Lox protein expression. After the 3-month
washout, all parameters were comparable to those observed
before treatment. Our results resemble those obtained after
oral administration of vitamin E and are consistent with a
reversible, dose-dependent inhibition of 5-Lox by x-3.
Upregulation of 5-Lox may also be related to the increased
mitochondrial damage and apoptosis of PBMCs observed in
ESRD patients compared to non-uremic controls. X-3 may
thus protect PBMCs of ESRD patients against oxidative stress.
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Atherosclerotic coronary heart disease (CHD) and systemic
arteriopathies are the main causes of morbidity and mortality
in Western countries. Peripheral blood mononuclear cells
(PBMCs) activation and low-density lipoproteins (LDLs)
oxidation are involved in the initiation and progression of the
atherosclerotic arterial lesion, from the reversible fatty streak
up to the fibrous plaque and the more complex lesions.1
Causative factors of atherosclerosis are complex, but in
end-stage renal disease (ESRD) patients uremia and
dialysis-related oxidative stress may play a critical role. The
susceptibility to oxidation ‘in vitro’ is enhanced in LDL from
ESRD patients on maintenance HD, suggesting that the accu-
mulation of a greater amount of oxidized LDL is among the
multiple factors involved in the occurrence of earlier and
more severe atherosclerotic lesions in uremic patients, ESRD
patients and after renal transplantation, compared to age-
matched population.2 Epidemiological studies showed that
diets enriched with fish oil are often associated to a lower
incidence of CHD and a reduction in atherosclerotic lesions.3
Dietary fish oil is rich in n-3 polyunsaturated fatty acids (n-3
PUFAs) like C20:5n-3 eicosapentaenoic acid (EPA) and
C22:6n-3 docosaesaenoic acid (DHA). Prolonged adminis-
tration of highly purified C20:5n-3 EPA was able to reduce
LDL oxidation in uremic patients on maintenance HD.2
In PBMC membranes, reactive oxygen species formation
and release of pro-inflammatory/pro-atherogenic cytokines,
that is, interleukin 1-b and tumor necrosis factor-a, need
the activation of the arachidonic acid cascade via the enzyme
5-lipoxygenase (5-Lox), leading to the synthesis of leuko-
triene B4 (LTB4). N-3 PUFAs may interfere with the ara-
chidonic acid cascade by inhibiting 5-Lox and the series-4
leukotriens synthesized thereof. In particular, the production
of LTB4 could be significantly impaired.
4
In previous experiments, we showed that 5-Lox activity
and expression are significantly increased in PBMCs of ESRD
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patients on maintenance HD, compared to non-uremic
controls.5 In addition, we showed that orally administered
vitamin E (a-tocopherol) exerts a protective effect against
5-Lox-mediated oxidative stress in PBMC membranes of
HD patients, owing to its ability to inhibit 5-Lox activity
directly.6,7 Interestingly, a-tocopherol is known to be able
to reduce LDL oxidation ‘in vitro’ in uremic patients1 and
healthy individuals.8
In the present study, we compare membrane lipid
peroxidation, protein expression and enzymatic activity
of 5-Lox, and concentration of LTB4 in PBMCs of ESRD
patients on maintenance HD, before and after a 3-month
supplementation with a mixture of the n-3 PUFAs EPA and
DHA, Eskim 1000 soft capsules (Sigma-Tau Industrie Farma-
ceutiche Riunite s.p.a., Rome, ITA) and finally after a further
3-month washout with no supplementation of n-3 PUFAs.
PBMCs from non-uremic volunteers were also investigated
for comparison to normal parameters.
RESULTS
A total of 16 ESRD patients aged 53–78 (mean 65.2579.10
years) and 15 age-matched healthy volunteers (mean
63.7778.51 years, P¼ 0.644) were enrolled into the study;
a written fully informed consent was obtained from all
patients and healthy volunteers. Main clinical features of HD
patients are summarized in Table 1.
The effects of administration of n-3 PUFAs, from now on
denoted as o-3, on lipid peroxidation and on the Lox
pathway of the arachidonic acid cascade in ESRD patients
and non-uremic volunteers are summarized in Table 2.
Statistical analysis of results is reported in Table 3.
We have previously shown that the oxidative index, that is,
the A234/205 ratio,
9 is a marker of membrane peroxidation
linked to 5-Lox activity.5,10 In PBMCs from HD patients, the
oxidative index was over 232% that observed in PBMCs
from non-uremic volunteers, whereas it dropped to 115%
after the 3-month o-3 supply (Po0.0001). In PBMCs from
HD patients, the 5-Lox activity was 183% that observed
in PBMCs from non-uremic volunteers (Po0.0001), but
dropped to only 105% after the 3-month o-3 supply
(Po0.0001). Consistently, in PBMCs from HD patients, the
amount of the 5-Lox product LTB4 was 150% that obser-
ved in PBMCs from non-uremic volunteers (Po0.0001).
Interestingly, in cells from HD patients after the 3-month
o-3 supply, LTB4 content was significantly lower than
either that of HD patients before the 3-month o-3 supply
or that of non-uremic volunteers (85% in the latter case),
Po0.0001 versus HD patients, Po0.0001 versus non-uremic
volunteers.
In PBMC membranes obtained from ESRD patients after
the 3-month washout lipid peroxidation, 5-Lox activity
and LTB4 concentration were significantly higher than those
observed after treatment with o-3 (195% Po0.0015, 172%
Po0.0001 and 171% Po0.0001, respectively, Table 3), and
were comparable to those observed at the beginning of the
study. Oxidative index and 5-Lox activity were 97 and 98.5%
than those observed in PBMCs from the same patients before
the 3-month o-3 supply (P¼ 0.861 and 0.428, respectively).
Consistently, the amount of the 5-Lox product LTB4 was 97%
than that observed in PBMCs from the same patients before
the 3-month o-3 supply (P¼ 0.230; Table 3)
In addition, protein content of 5-Lox, which is a result
of 5-Lox gene expression, was also significantly higher in
HD patients compared to non-uremic volunteers, but was
not affected by o-3: 165 and 168% that observed in PBMCs
from non-uremic volunteers in pre and post o-3 supply,
respectively (Po0.0001), but P¼ 0.1093 in pre versus post
o-3 supply, P¼ 0.711 in pre o-3 versus post washout and
P¼ 0.856 in post o-3 versus post washout (Table 3).
DISCUSSION
The present results confirm our previous observation that the
enzyme 5-Lox is upregulated in PBMC membranes of ESRD
patients on maintenance HD.5–7 In PBMCs of HD patients,
both 5-Lox activity and protein content are increased, as are
Table 1 | Mean clinical features of the sixteen HD patients at
the beginning of the study
Age (years) 65.2579.10
Dialytic age (months) 48.25736.93
KT/V 1.2070.19
Serum CRP (mg/100 ml) 21.9 (median 3.9)
Serum homocysteine (mM/l) 43.15726.23
Serum albumin (g/100 ml) 4.0770.31
Serum total cholesterol (mg/100 ml) 167.7730.3
Serum HDL cholesterol (mg/100 ml) 51.8718.7
Serum LDL cholesterol (mg/100 ml) 91.5726.2
Serum triglycerids (mg/100 ml) 123.3760.5
CRP=C-reactive protein; HD=hemodialysis; HDL=high-density lipoprotein; LDL=low-
density lipoprotein.
Data are mean7s.d.
Table 2 | Arachidonate cascade in HD patients (n=16) before and after a 3-month course with oral n-3 PUFAs EPA and
DHA (x-3) and after a 3-month washout, compared to non-uremic volunteers (n=15)
Non-uremic Pre x-3 Post x-3 Washout
Oxidative index (A234/205) 0.07170.008 0.16570.080 (232%) 0.08270.040 (115%) 0.16070.080 (225%)
LTB4 (pmol/mg protein) 46.074.1 69.273.2 (150%) 39.073.1 (85%) 67.073.0 (146%)
5-Lox activity (pmol/min per mg protein) 1561.07109.0 2854.97157.6 (183%) 1646.57107.5 (105%) 2810.07158.4 (180%)
5-Lox expression (A405 units) 0.44970.043 0.73970.064 (165%) 0.75370.082 (168%) 0.74870.072 (167%)
DHA=docosaesaenoic acid; EPA=eicosapentaenoic acid; HD=hemodialysis; LTB4=leukotriene B4; PUFA=polyunsaturated fatty acids.
Data are mean7s.d.
Values in brackets represent percent of values observed in non-uremic volunteers, set to 100.
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the concentration of the final product of 5-Lox, LTB4
and the 5-Lox-mediated membrane lipid peroxidation.
After a 3-month treatment with o-3 significant reductions
in oxidative index, 5-Lox activity and LTB4 level were
observed. As 5-Lox protein content was not affected by o-3
supply (Table 1), it can be suggested that the activity but not
the expression of 5-Lox is affected by n-3 PUFAs. Preliminary
data from our group suggest that indeed n-3 PUFAs inhibit
pure 5-Lox acting as a non-competitive inhibitor, and that
7.5 ml of a solution of this mixture of n-3 PUFAs EPA and
DHA (diluted 1:250) is enough to inhibit up to 50% enzyme
activity (data not shown). Overall, these results resemble
those recently obtained after oral administration of vitamin
E,6,7 and are consistent with a reversible, dose-dependent
inhibition of 5-Lox by o-3. Interestingly, the inhibition
exerted by o-3 on LTB4 synthesis was significantly higher
than expected from the enzymatic inhibition alone. Indeed,
post-treatment LTB4 level was significantly lower not only
than that of pre-treated samples (Po0.0001) but also than
that of unsupplemented non-uremic volunteers. This ‘extra-
inhibition’ may be interpreted as a competition between EPA
and arachidonic acid as substrates for 5-Lox. In fact, EPA
present in cell membrane phospholipids is known to compete
with arachidonic acid, thus inhibiting the synthesis of
LTB4 and leading to the production of the less active ‘false
metabolite’ LTB5.
4
Atherosclerosis is a leading cause of cardiovascular
morbidity and mortality. In ESRD patients undergoing
maintenance renal replacement therapy, earlier and more
severe atherosclerotic lesions are observed and are associated
to a significantly higher incidence of CHD and acute
cerebrovascular accidents compared to age-matched controls.
We showed that 5-Lox activity and expression are signifi-
cantly increased in PBMCs of ESRD patients on maintenance
HD.5 5-Lox activity in PBMCs is involved in LDL oxidation
in the early phases of the atherosclerotic arterial lesion.1 The
causative factors of atherosclerosis are complex, but in ESRD
patients uremia and dialysis-related oxidative stress may
also play a critical role. Some cellular types in the arterial
wall, such as monocytes–macrophages, endothelial cells and
smooth muscle cells, can oxidize LDL ‘in vitro’.1 The
susceptibility to oxidation ‘in vitro’ is enhanced in LDL
from ESRD patients on maintenance HD, suggesting that
the occurrence of earlier and more severe atherosclerotic
lesions observed in uremic patients may be related to the
accumulation of a greater amount of oxidized LDL. 5-Lox
activity is a key-point in LDL oxidation,1 therefore its
inhibition by n-3 PUFAs may protect against the athero-
sclerotic damage. Prolonged administration of highly
purified EPA is able to reduce LDL oxidation in uremic
patients by three possible mechanisms: (1) EPA incorporated
into cell membrane phospholipids is able to protect LDL
against peroxidation. (2) The a-tocopherol fraction in the
EPA capsules may be partly involved in the prevention of the
LDL peroxidation. In this context, we5–7,11–13 and others14,15
have previously demonstrated that oral vitamin E prevents
oxidative stress, yet it seems unlikely that the small amount
of a-tocopherol present in each capsule (0.6 mg for each
capsule, that is, 1.8 mg daily) may significantly interfere with
EPA. (3) Incorporated EPA can decrease the compositional
rate of arachidonic acid that serves as a potential substrate
for peroxidation.2,4 In addition, EPA and DHA may interfere
with the arachidonic acid cascade by inhibiting the synthesis
of arachidonic acid from linoleic acid, or by competing with
arachidonic acid for the 2-position in membrane phospho-
lipids, thereby reducing plasma and cellular arachidonate.
Furthermore, EPA might compete with arachidonic acid as
cyclooxygenase substrate, thus preventing the production of
TXA2, or as 5-Lox substrate, thus reducing the synthesis of
LTB. EPA present in cell membrane phospholipids inhibits
the synthesis of LTB4, and generates small amounts of the less
active LTB5, which competes for LTB4 receptors. Hence, EPA
may significantly impair both the synthesis and the activity
of LTB4. Taken together, our present data suggest that the
inhibition of 5-Lox by o-3 may contribute to all the three
mechanisms proposed for the ability of o-3 to reduce LDL
oxidation.
Formation of reactive oxygen species in PBMC mem-
branes and release of pro-inflammatory/pro-atherogenic
cytokines like interleukin 1-b and tumor necrosis factor-a
need also the activation of the arachidonic acid cascade via
5-Lox and the subsequent synthesis of LTB4.
1 We recently
showed that upregulation of 5-Lox may also be related
to the increased mitochondrial damage and apoptosis of
PBMCs observed in ESRD patients compared to non-uremic
controls.16–20 Our results suggest that administration n-3
PUFAs, by inhibiting 5-Lox overactivity, can protect PBMCs
of ESRD patients also against programmed cell death, leading
to a higher biocompatibility of HD treatment and a better
performance in therapeutic intervention.
Table 3 | Two-tailed P-values were calculated by the non-parametric Mann–Whitney U-test (pre and post x-3 versus non-uremic
volunteers) and Wilcoxon test (post versus pre x-3, washout versus pre and post x-3)
Non-uremic
versus pre x3
Post x-3
versus pre x-3
Wash-out
versus post x-3
Washout
versus pre x-3
Oxidative index (A234/205) Po0.0001 Po0.0001 P=0.0015 P=0.861
LTB4 (pmol/mg protein) Po0.0001 Po0.0001 Po0.0001 P=0.230
5-Lox activity (pmol/min per mg protein) Po0.0001 Po0.0001 Po0.0001 P=0.428
5-Lox expression (A405 units) Po0.0001 P=0.109 P=0.856 P=0.711
LTB4=leukotriene B4.
P-values o0.05 were considered statistically significant.
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MATERIALS AND METHODS
Study design
To assess the effects of n-3 PUFAs EPA and DHA on 5-Lox-related
oxidative stress, lipid peroxidation, LTB4 production, 5-Lox activity
and expression were investigated in PBMC membranes isolated from
ESRD patients under maintenance HD. PBMCs were isolated from
ESRD patients before and after a 3-month oral supplementation
with a purified mixture of the n-3 PUFAs EPA and DHA. In the lack
of evidence for preferred doses of treatment in HD patients, a daily
dose of three gelatin capsules, each containing 850–885 mg of
n-3 PUFAs extracted from fish oil at the average EPA/DHA ratio
of 1:2, was administered. In order to obtain an homogeneous
case-to-control comparison, ESRD patients were used as controls of
themselves; lipid peroxidation, LTB4 production, 5-Lox activity and
expression were thus determined again in PBMC membranes
isolated from the same patients after a further 3-month washout
during which n-3 PUFAs were not supplemented (‘wash-out’ group
in Table 2).
PBMCs were also isolated from age-matched non-uremic
volunteers and investigated for comparison to normal parameters.
Selection of ESRD patients and non-uremic volunteers
All ESRD patients were recruited from a single HD center and were
on maintenance renal replacement therapy since at least 6 months.
Non-uremic age matched volunteers were recruited among the
hospital staff and outpatients with normal renal function (i.e. serum
creatinine not exceeding 1.3 mg/100 ml and estimated glomerular
filteration rate higher than 70 ml/min according to Cockroft and
Gault21) and no history of diabetes mellitus. Patients and volunteers
with history of CHD or cerebrovascular acute accident, neoplasia,
major surgery and cigarette smoking within the last year were
excluded. Patients and volunteers were on free diet. Underlying
disease was nephroangiosclerosis in six ESRD patients, chronic
primary glomerulonephritis in three, diabetes mellitus in three,
policystic kidney disease in two, AA amyloidosis in one and bilateral
stag horn urolythiasis in one patient. All HD patients received
standard bicarbonate dialysis for 4 h three times weekly with 1.6/
2.0 m2 cuprammonium rayon membranes (AM Bio Wet, Asahi
Medical Co., Tokyo). Twelve ESRD patients and five non-uremic
volunteers took anti-hypertensive medications, whereas nine ESRD
patients and two non-uremic volunteers took beta-hydroxymethyl-
CoA reductase inhibitors. ESRD patients did not take any drug with
established or potential oxidizing effect during the observation
period. In particular, any treatment with beta-hydroxymethyl-CoA
reductase inhibitors and angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers was suspended from at least 1
month before the beginning until the end of the observation in
ESRD patients and for at least 1 month before the study in non-
uremic volunteers. When needed, blood pressure was controlled
with alternative drugs.
Isolation of PBMC
Blood samples (10 ml per donor) were drawn from the antecubital
vein in non-uremic volunteers and from the arterial side of
the arterovenous fistula before dialysis in HD patients. Then, blood
was collected into heparinized sterile test tubes and processed
immediately. Isolation and purification of PBMCs were performed
by centrifugation on a concentration gradient (d¼ 1077), as
reported.22
Materials
All chemicals were of the purest analytical grade. Homocysteine
was determined by a fluorescence polarization immunoassay (FPIA,
IMxs Homocysteine assay, Abbott, normal range 6–15 mmol/l). Ara-
chidonic (5,8,11,14-eicosatetraenoic) acid, ATP, and p-nitrophenyl-
phosphate were from Sigma Chemical Co. (St Louis, MO, USA).
Authentic LTB4 was from Cayman Chemical Company (Ann Arbor,
MI, USA). Anti-human 5-Lox rabbit polyclonal antibodies were
a kind gift of Dr AW Ford-Hutchinson (Merck Frosst Center for
Therapeutic Research, Pointe Claire-Dorval, Canada), and goat-anti
rabbit polyclonal antibodies, conjugated with alkaline phosphatase
were purchased from Bio-Rad (Richmond, CA, USA).
Assay of 5-Lox activity and expression
The activity of 5-Lox (E.C. 1.13.11.34) was measured as described
previously5 by incubating cell extracts prepared from 5 106
PBMCs for 10 min at 371C in the presence of 1 mM ATP, 2 mM
CaCl2 and 40 mM arachidonic acid.
23 Reaction products were
separated by reverse phase-high-performance liquid chromatogra-
phy on a Perkin–Elmer Nelson Model 1022 Plus Chromatograph,
equipped with a Perkin–Elmer series 200 LC Pump, an LC295 UV/
VIS detector and a 7125 BIO injector with a 20 ml loop. The system
was interfaced with a Compaq Prolinea 5100 computer, using
a Perkin–Elmer Turbochrom software for system control and data
processing. Separations were carried out on a C18 (5mm, 30 3 mm
i.d.) column (SGE, Austin, TX, USA) at a flow rate of 1.2 ml/min,
using methanol/water/trifluoroacetic acid (70/30/0.007, by volume)
as mobile phase. Chromatograms were recorded at 234 nm. 5-Lox
activity was expressed as pmol 5-hydroperoxyeicosatetraenoic acid
formed per min per mg protein.10
Enzyme-linked immunosorbent assay was performed as re-
ported,24 by coating each well overnight with PBMC extracts (25 mg/
well) and reacting with rabbit anti-5-Lox (diluted 1:200) polyclonal
antibodies as first antibody. Goat anti-rabbit immunoglobulins G
conjugated with alkaline phosphatase were used as second antibody
(diluted 1:2000), and color development of the alkaline phosphatase
reaction was followed at 405 nm, using p-nitrophenylphosphate as
substrate.24
Analysis of arachidonic acid metabolites and membrane
properties
Arachidonic acid metabolite LB4 was extracted from PBMCs
(5 106/test) by solid-phase octadecyl-SPE columns (Baker,
Deventer, The Netherlands), using ethyl acetate as eluent, and were
analyzed by reverse phase-high-performance liquid as described
above for the products of 5-Lox activity. The eluate was monitored
at 270 nm, assessing peak identity by comparison with authentic
standards.10 Quantitative determinations were performed by
integrating peak areas.
Membrane lipids were isolated from PBMCs (10 106/test) as
reported,5 and absorption spectra were recorded in the wavelength
range 200–350 nm in order to measure the oxidative index, that is,
the A234/205 ratio.
9 Spectra were recorded at room temperature in
an UV–VIS spectrometer Lambda 18 (Perkin–Elmer, Norwalk,
CO, USA) and showed the same features as those already reported
for PBMCs.5
Data analysis
Results reported in this paper are the mean7s.d. of at least four
independent determinations, each in triplicate. Statistical analysis
was performed by calculating two-tailed P-values by means of the
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non-parametric Mann–Whitney U-test and Wilcoxon test. P-values
o0.05 were considered statistically significant. Experimental data
were elaborated through the InStat 3 program (GraphPad Software
for Science, San Diego, CA, USA).
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